FiercePharma9h
After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
FiercePharma13h
Bavarian Nordic nets large mpox vaccine supply pact, boosts revenue outlook after string of deals
In the latest of several recent mpox vaccine supply deals, Bavarian Nordic plans to provide 1 million doses of its shot, ...
FiercePharma15h
Fierce Pharma Asia—Daiichi, AZ's ADC setback; Fosun, Kite JV's separation; Yuhan's busy week
AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...
FiercePharma15h
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
FiercePharma15h
Travere pumps brakes on late-stage enzyme replacement therapy study, citing production scale-up problems
Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run ...
FiercePharma16h
Lundbeck, Otsuka make their Alzheimer’s agitation pitch as Barbara Corcoran joins new campaign
After nabbing a new FDA license for Rexulti in Alzheimer’s agitation last year, the drug’s marketing duo Lundbeck and Otsuka ...
FiercePharma16h
ESMO, WCLC lung cancer data spark hope—and debate
At the recent World Conference on Lung Cancer and European Society for Medical Oncology | In this week's "The Top Line," ...